Anemia is a frequent complication of chronic kidney disease (CKD) and is associated with a decrease in the quality of life of patients causing an increase in morbidity and mortality. It is also believed to accelerate the rate of progression of CKD. Anemia in chronic kidney disease is typically attributed to the decrease of erythropoietin production that accompanies the fall in Glomerular filtration rate (GFR). There are three main causes contributing to anemia in CKD. Epo deficiency is the most dominant cause , while suppression of the marrow response to anemia, and shortened red cell survival are the other causes of Anemia in CKD.
According to the National institute of Diabetes and Digestive and Kidney Diseases, Anemia commonly occurs in people with chronic kidney disease (CKD)—the permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD where only 20 to 50 percent of normal kidney function is restored. Anemia tends to worsen as CKD progresses. Most people who have total loss of kidney function, or kidney failure, have anemia. The development of recombinant human erythropoietin (rhEpo) as a therapeutic modality has changed the management of anemia in CKD. Novel therapeutic approaches, technological advancements and increase in government support are expected to be responsible for the growth of the therapeutic market during the forecast period (2020-2030).
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market
The Anemia In Chronic Kidney Disease market report also covers emerging drugs, current treatment practices, Anemia In Chronic Kidney Disease market share of the individual therapies, current and forecasted Anemia In Chronic Kidney Disease Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Anemia In Chronic Kidney Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Anemia In Chronic Kidney Disease Market Key Facts
According to the study conducted by Steven F. et al. 2018, in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD
According to Melissa E et al. 2014, 14.0% of the US adult population had CKD in 2007–2010. Anemia was twice as prevalent in people with CKD (15.4%) as in the general population (7.6%)
At least 90% of patients who end up on dialysis will eventually develop anemia of chronic disease.
In Japan, prevalence of anemia was one of the most frequently reported outcomes within the identified literature and varied from 0% to 95% depending on dialysis status and severity of CKD.
Key Benefits of Anemia In Chronic Kidney Disease Market Report
-
Anemia In Chronic Kidney Disease market report provides an in-depth analysis of Anemia In Chronic Kidney Disease Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Anemia In Chronic Kidney Disease market report will help in developing business strategies by understanding the Anemia In Chronic Kidney Disease Market trends & developments, key players and future market competition that will shape and drive the Anemia In Chronic Kidney Disease market in the upcoming years.
-
The Anemia In Chronic Kidney Disease market report covers Anemia In Chronic Kidney Disease current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Anemia In Chronic Kidney Disease market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Anemia In Chronic Kidney Disease Market
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Anemia commonly occurs in people with chronic kidney disease (CKD) which results into permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD, when someone has 20 to 50 percent of normal kidney function. Anemia tends to worsen as CKD progresses. Most people who have total loss of kidney function, or kidney failure, have anemia.
Currently, the treatment paradigm for Anemia in Chronic Kidney Disease involves use of Iron therapies, Erythropoietin stimulating agent (ESA) therapies, Red Blood Transfusions, Vitamin B12 & Folic Acid Supplements and nutrition.
The Anemia In Chronic Kidney Disease market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Anemia In Chronic Kidney Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Anemia In Chronic Kidney Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Anemia In Chronic Kidney Disease Epidemiology
The Anemia In Chronic Kidney Disease epidemiology section covers insights about historical and current Anemia In Chronic Kidney Disease patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Anemia In Chronic Kidney Disease Drugs Uptake and Key Market Players
The Anemia In Chronic Kidney Disease Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anemia In Chronic Kidney Disease market or expected to get launched in the market during the study period. The analysis covers Anemia In Chronic Kidney Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key players in the Anemia In Chronic Kidney Disease market includes:
Akebia Therapeutics
GlaxoSmithKline
Astellas Pharma
FibroGen, Inc
And many others
Some of the key drugs covered in the report includes:
Evrenzo
Vadadustat
Daprodustat
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Anemia In Chronic Kidney Disease Competitive Intelligence Analysis
4. Anemia In Chronic Kidney Disease Market Overview at a Glance
5. Anemia In Chronic Kidney Disease Disease Background and Overview
6. Anemia In Chronic Kidney Disease Patient Journey
7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population
8. Anemia In Chronic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Anemia In Chronic Kidney Disease Unmet Needs
10. Key Endpoints of Anemia In Chronic Kidney Disease Treatment
11. Anemia In Chronic Kidney Disease Marketed Products
12. Anemia In Chronic Kidney Disease Emerging Therapies
13. Anemia In Chronic Kidney Disease Seven Major Market Analysis
14. Attribute Analysis
15. Anemia In Chronic Kidney Disease Market Outlook (7 major markets)
16. Anemia In Chronic Kidney Disease Access and Reimbursement Overview
17. KOL Views on the Anemia In Chronic Kidney Disease Market.
18. Anemia In Chronic Kidney Disease Market Drivers
19. Anemia In Chronic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Anemia In Chronic Kidney Disease Epidemiology Forecast to 2030
DelveInsight’s Anemia In Chronic Kidney Disease Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Anemia In Chronic Kidney Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Anemia In Chronic Kidney Disease Pipeline Insights, 2020
Anemia In Chronic Kidney Disease Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/